Skip to main content

Table 2 Univariate analysis of prognostic factors in progression-free survival

From: The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies

Adverse events

Median (months)

95% C.I. of median

P value

Hazard ratio

95% C.I. of HR

P value

Skin

  

.274

   

 Grade 0 (n = 32)

2.8

1.9–3.8

 

1

  

 Grade 1–2 (n = 17)

3.6

1.6–5.6

 

0.71

0.38–1.32

.278

Skin/vitiligo

  

.092

   

 Grade 0 (n = 30)

2.5

1.6–3.4

 

1

  

 Grade 1–2 (n = 19)

4.6

2.5–6.7

 

0.59

0.32–1.10

.096

Mucositis

  

.287

   

 Grade 0 (n = 46)

3.1

2.5–3.8

 

1

  

 Grade 1–2 (n = 3)

3.0

0.4–5.6

 

1.90

0.57–6.29

.296

Colitis

  

.624

   

 Grade 0 (n = 43)

3.2

2.6–3.7

 

1

  

 Grade 1–2 (n = 6)

3.0

2.3–3.7

 

1.24

0.52–2.96

.626

Liver

  

.353

   

 Grade 0 (n = 47)

3.2

2.7–3.6

 

1

  

 Grade 1–2 (n = 1)

3.1

–

 

1.48

0.20–10.99

.700

 Grade 3–5 (n = 1)

2.1

–

 

3.89

0.50–30.19

.194

Lung

  

.005

   

 Grade 0 (n = 47)

3.2

2.8–3.5

 

1

  

 Grade 3–5 (n = 2)

0.9

–

 

6.71

1.44–31.38

.016

Endocrine

  

.094

   

 Grade 0 (n = 40)

2.7

2.1–3.3

 

1

  

 Grade 1–2 (n = 9)

6.1

2.7–9.6

 

0.52

0.24–1.13

.100

Fatigue

  

.024

   

 Grade 0 (n = 42)

3.2

2.7–3.7

 

1

  

 Grade 1–2 (n = 7)

2.4

1.5–3.4

 

2.56

1.09–6.00

.030

Vitiligo

  

.234

   

 Grade 0 (n = 47)

3.0

2.5–3.4

 

1

  

 Grade 1–2 (n = 2)

4.7

–

 

0.32

0.04–2.33

.261

Skin/vitiligo/endocrine

  

.003

   

 Grade 0 (n = 26)

2.3

1.7–2.8

 

1

  

 Any grade (n = 23)

4.8

4.3–5.3

 

0.40

0.21–0.74

.003

Overall

  

.001

   

 Grade 0 (n = 19)

2.5

1.7–3.3

 

1

  

 Grade 1–2 (n = 27)

4.6

2.8–6.4

 

0.52

0.27–0.98

.042

 Grade 3–5 (n = 3)

2.0

0.2–3.8

 

4.24

1.1–16.3

.035

  1. C.I. confidence interval
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us